[{"id":"e7db6484-cb3f-4fec-baf5-e9188f814ac7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03745989","created_at":"2021-07-05T17:18:24.986Z","updated_at":"2024-07-02T16:35:41.979Z","phase":"Phase 1b","brief_title":"Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)","source_id_and_acronym":"NCT03745989","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • MK-8353"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/22/2019","start_date":" 02/22/2019","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2023-07-27"},{"id":"45305998-fa64-4d07-b93d-837bfa07fbb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02972034","created_at":"2021-01-18T14:36:36.141Z","updated_at":"2024-07-02T16:35:54.334Z","phase":"Phase 1","brief_title":"Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)","source_id_and_acronym":"NCT02972034","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • MSI","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-8353"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 01/13/2017","start_date":" 01/13/2017","primary_txt":" Primary completion: 12/02/2022","primary_completion_date":" 12/02/2022","study_txt":" Completion: 12/02/2022","study_completion_date":" 12/02/2022","last_update_posted":"2023-03-02"}]